Growth-Factor Injections for Neutropenia: How They Support the Marrow and When They Are Used

The blood test comes back at the Tuesday clinic visit, and the nurse says a word that sounds like a small country: neutropenia. Then comes a second word, delivered more gently, about a shot that helps the marrow “catch up.” Most people leave that appointment with a prefilled syringe in a paper bag and a head full of half-formed questions. What is actually in it? Why bone pain? Will it help the chemotherapy work, or just make the numbers look better on paper?

Growth factor injections for neutropenia have been a routine part of cancer care and blood medicine for decades, yet they remain one of the least explained treatments a patient receives. They are neither a vitamin nor a chemotherapy drug. They are a copy of a message the body already sends itself, turned up in volume.

This explainer walks through what the message says, who tends to receive it, what the days afterward usually feel like, and the moments when a phone call to the care team matters more than anything written here.

What are growth factor injections for neutropenia, really?

Strip away the pharmacy label and a growth factor injection is a protein. Specifically, it is a manufactured copy of granulocyte colony-stimulating factor, usually shortened to G-CSF, a signaling molecule the body naturally produces to tell the bone marrow how many neutrophils to make. Neutrophils are the white blood cells that arrive first at any site of infection and swallow bacteria whole.

The body already uses this signal every day. During an infection, G-CSF levels rise, the marrow responds, and the neutrophil count climbs within hours. When chemotherapy or a bone marrow disorder blunts that response, an injected version supplies the signal from the outside. The marrow does the rest, which is why these medicines are sometimes described as supporting the marrow rather than replacing what it makes.

Two features distinguish this family from most other cancer-supportive medicines. First, they do not kill anything; they have no direct effect on tumor cells or bacteria. Second, they work only if the marrow still has neutrophil precursors capable of responding. A marrow that has been replaced by disease or permanently damaged cannot answer the call, no matter how loudly it is sent.

Several forms exist. Short-acting G-CSF (the generic name filgrastim and its biosimilar versions, which are close copies made by different manufacturers) is cleared by the body within roughly a day, according to MedlinePlus. A long-acting version, pegfilgrastim, has an added polyethylene glycol chain that slows its removal so a single injection lasts across a chemotherapy cycle. A related but less commonly used protein, granulocyte-macrophage colony-stimulating factor (GM-CSF, generic name sargramostim), stimulates a broader set of cells. Which one, if any, is appropriate is always a prescribing decision tied to the specific situation.

Why neutrophils matter and what neutropenia does to the body

Picture the immune system as a city’s emergency services. Lymphocytes are the detectives who learn a suspect’s face and remember it for years. Neutrophils are the patrol officers on every corner: numerous, fast, and short-lived. They survive in the bloodstream for less than a day before being replaced, which means the marrow must produce billions of them continuously just to hold the line.

That constant turnover is exactly what makes neutrophils vulnerable to chemotherapy. Most chemotherapy drugs target rapidly dividing cells, and few cells divide faster than the neutrophil precursors in the marrow. The patrol force is not killed in the streets; it simply stops being replaced, and within a week or two the corners are empty.

Clinicians measure this with the absolute neutrophil count, or ANC, the number of neutrophils per microliter of blood. Mayo Clinic describes neutropenia as an ANC below about 1,500 cells per microliter in adults, with counts under 500 considered severe. Below that lower line, ordinary bacteria living harmlessly on the skin and in the gut can slip into the bloodstream, and the usual warning signs of infection, such as pus, redness, or swelling, may not appear because there are no neutrophils to produce them.

The consequence that worries oncologists most is febrile neutropenia: a fever arriving during a period of low counts. Cleveland Clinic notes that a temperature of 100.4°F (38°C) or higher in someone with neutropenia is treated as a medical emergency, because the fever may be the only visible sign of a rapidly spreading infection. Growth factor injections exist largely to shorten the window in which this can happen.

How does filgrastim work inside the bone marrow?

Bone marrow is not a static organ. Deep in the hip bones, breastbone, and long bones, a population of stem cells constantly decides what to become: red cells, platelets, or the various white cells. Each decision is steered by chemical signals binding to receptors on the cell surface, much as a key fits a specific lock.

G-CSF is the key for the neutrophil lineage. When filgrastim or a biosimilar is injected under the skin, it enters the bloodstream, travels to the marrow, and binds to G-CSF receptors on neutrophil precursors. Three things then happen at once. Precursor cells divide more frequently, so the pipeline fills faster. Each cell matures in less time than it normally would. Mature neutrophils are released into the circulation earlier, rather than waiting in the marrow’s storage pool.

The visible result on a blood test is a rise in the neutrophil count, sometimes within a day of the first injection, according to MedlinePlus. The less visible result, and the one that matters clinically, is that the nadir, the lowest point of the count after chemotherapy, tends to be shallower and shorter. The patrol officers return to their corners sooner.

Timing shapes everything. Because G-CSF pushes precursors to divide, giving it too close to chemotherapy could expose those newly dividing cells to the very drug that kills dividing cells. MedlinePlus states that filgrastim is typically not given within 24 hours before or after a chemotherapy dose. The prescribing team sets the exact schedule around each patient’s regimen.

One point often surprises people: the injection does not create neutrophils from nothing. It accelerates a factory that already exists. That is why response depends so heavily on the underlying health of the marrow.

What injection is given for neutropenia? The main types compared

People searching “what injection is given for neutropenia” usually land on a brand name, which tells them little. Thinking in terms of classes is more useful. The table below summarizes the forms clinicians most often discuss, using generic names only and without any implication that one is preferable; that judgment belongs to the prescriber.

Type	Generic name(s)	How it acts	Typical pattern of use (per MedlinePlus)
Short-acting G-CSF	Filgrastim and its biosimilars	Stimulates neutrophil precursors; cleared within about a day	Daily injections until the count recovers, or for stem cell mobilization
Long-acting G-CSF	Pegfilgrastim and its biosimilars	Same receptor; added PEG chain slows clearance	One injection per chemotherapy cycle, at least 24 hours after chemotherapy and not within 14 days of the next dose
GM-CSF	Sargramostim	Stimulates neutrophils, monocytes, and related lineages	Selected settings, such as after certain transplants

Biosimilars deserve a sentence of their own. A biosimilar is a biologic medicine shown by regulators to have no clinically meaningful differences from an original reference product. Because these proteins are grown in living cells rather than synthesized chemically, exact copies are impossible, so “highly similar” is the regulatory standard. Patients frequently receive a biosimilar without noticing any difference in how the injection is given or how it feels.

All of these are given as subcutaneous injections, meaning into the fatty layer under the skin of the abdomen, thigh, or upper arm. Some can also be given intravenously in hospital. An on-body injector that delivers pegfilgrastim automatically the day after chemotherapy is also used in some centers, sparing a return visit.

Which type a person receives depends on the chemotherapy schedule, the reason for neutropenia, kidney and spleen health, and practical factors such as distance from the clinic. There is no single right answer.

Who is usually offered growth factor support

The largest group by far is people receiving chemotherapy. Oncology guidelines around the world share a common logic: estimate how likely a particular regimen is to cause febrile neutropenia, factor in the individual’s age, other illnesses, prior infections, and marrow reserve, and offer G-CSF when that combined risk crosses a threshold the team judges significant. When given from the first cycle onward this is called primary prophylaxis; when added after a person has already had a neutropenic complication, it is secondary prophylaxis.

Beyond chemotherapy, several other situations bring G-CSF into the conversation:

• Severe chronic neutropenia, including inherited forms that appear in infancy and cyclic neutropenia, in which counts dip on a roughly three-week rhythm. MedlinePlus lists these among the approved uses of filgrastim.
• Before stem cell collection, whether from a patient’s own blood or from a donor, because G-CSF coaxes stem cells out of the marrow and into the bloodstream where they can be harvested.
• After a bone marrow or stem cell transplant, to hasten the return of neutrophils while the new marrow establishes itself.
• Certain non-cancer conditions, such as neutropenia caused by HIV or by other medicines, when the prescriber judges the benefit worthwhile.

A person’s own priorities also weigh in. Someone whose chemotherapy is intended to control cancer long-term may accept a different balance of injections and side effects than someone for whom treatment is primarily about comfort, where fewer clinic visits and fewer medicines may matter more.

None of these categories is automatic. A regimen with a moderate risk of febrile neutropenia may warrant G-CSF in an older adult with kidney disease and not in a younger person with healthy marrow. The recommendation is built one patient at a time.

Who is usually asked to wait, and what the alternatives are

Not every low neutrophil count calls for a growth factor, and several situations make clinicians pause. Understanding why can spare a good deal of anxiety when the shot is not offered.

The most common reason to hold back is that the expected risk is simply low. A chemotherapy regimen with a small chance of febrile neutropenia in a person with a healthy marrow may not justify daily injections, bone pain, and added complexity. Watchful monitoring with regular blood counts is a legitimate, evidence-based plan, not a lesser one.

Timing creates a second category. Because G-CSF pushes marrow cells to divide, it is generally avoided in the window immediately around a chemotherapy dose, as MedlinePlus notes. Someone who asks for an injection the same afternoon as their infusion will usually be asked to wait, not because the medicine is wrong but because the moment is.

Certain blood cancers require particular care. In myeloid leukemias, the malignant cells themselves may carry G-CSF receptors, and the treating team weighs whether stimulating them is wise at that stage. In myelodysplastic syndromes, marrow that is failing may respond poorly, and the decision often depends on whether infections are actually occurring rather than on the number alone.

People with sickle cell disease face a specific caution: MedlinePlus reports that filgrastim can trigger a sickle cell crisis, so it is used only with careful consideration. A history of serious allergic reaction to a G-CSF product is another reason to avoid it.

The alternatives are less dramatic but real. Dose adjustments or delays in chemotherapy, closer count monitoring, preventive antibiotics in high-risk periods, and prompt emergency treatment of any fever are all standard approaches, chosen or combined by the treating team.

What actually happens on injection day

For most people, the first injection is given in clinic, where a nurse demonstrates the technique and watches for any immediate reaction. After that, many patients or family members give the injections at home. The syringe usually comes prefilled and is stored in the refrigerator; MedlinePlus advises letting it reach room temperature before use, because cold liquid stings more and can be uncomfortable to push.

The injection itself takes a few seconds. The needle is short and goes into the fatty tissue just under the skin, most often the abdomen (avoiding the area around the navel), the front of the thigh, or the back of the upper arm. Rotating sites reduces soreness. Bruising or a small red mark is common and not a cause for concern on its own.

What people notice afterward varies widely. Some feel nothing. Others describe a deep, dull ache in the lower back, hips, or breastbone that begins within a day or two. This bone pain is the single most frequently reported effect, according to MedlinePlus, and it reflects the marrow expanding inside rigid bone as it ramps up production. In other words, the ache is often a sign the message has been received.

Practical steps on the day tend to be simple. Care teams generally suggest keeping a log of injection dates and sites, noting any fever, and having a thermometer within reach. Used syringes go into a sharps container, never household trash. Anyone unsure about technique should ask for a repeat demonstration rather than guess; there is no embarrassment in asking twice.

Blood counts are usually checked at intervals set by the team, which is how the decision to continue or stop short-acting injections is made.

The following days and weeks: what the timeline usually looks like

Neutrophil counts after chemotherapy follow a recognizable arc. Cleveland Clinic describes the nadir, the lowest point, as typically arriving about 7 to 12 days after a chemotherapy dose, with recovery over the following week or so. Growth factor injections do not erase this arc; they compress and lift it.

With short-acting G-CSF, the count may rise sharply within a day or two of the first injection, sometimes well above normal. This early spike is largely mature neutrophils released from marrow storage rather than true recovery, and it often falls again as chemotherapy’s effect on precursors takes hold. The count then climbs more durably as the accelerated pipeline delivers. Daily injections generally continue until the team sees the count pass a target and stay there, a pattern MedlinePlus describes as continuing until white cells recover after chemotherapy.

With long-acting pegfilgrastim, given once the day after chemotherapy, the medicine is cleared more slowly precisely because it is bound to neutrophils; as counts recover, more of the drug is removed, a self-regulating loop. The single injection is designed to cover the entire nadir period.

Symptoms follow their own timeline. Bone pain, when it occurs, usually peaks in the first several days and eases as counts stabilize. Mild fatigue, headache, or nausea may accompany it. A blood test checked too soon after an injection can look alarmingly high; teams know this and interpret accordingly.

People on repeated cycles often report that the pattern becomes predictable: they learn which day the ache arrives and which day it lifts. That predictability is itself useful, because a fever or new symptom outside the expected rhythm stands out more clearly and prompts an earlier call.

G-CSF injection side effects: what is common and what is rare

Ask a room of people who have had these injections about side effects and one answer dominates: bone pain. MedlinePlus lists it first for both filgrastim and pegfilgrastim, and describes it as pain in the bones, back, arms, or legs. Its intensity ranges from a vague ache to a pain that interferes with sleep. Care teams have several ways to help, and anyone struggling should say so rather than endure it silently.

Other commonly reported effects, per MedlinePlus, include:

• Muscle aches and headache
• Redness, swelling, or itching at the injection site
• Tiredness, nausea, or a low-grade feeling of being unwell
• Nosebleeds in some people

Serious effects are uncommon but well described, and knowing them turns vague worry into specific vigilance. MedlinePlus flags the following as reasons to seek urgent care:

• Pain in the upper left abdomen or left shoulder tip, which can signal an enlarged or, very rarely, ruptured spleen. The spleen filters blood and can swell as it processes the surge of new cells.
• Sudden shortness of breath, fever, or rapid breathing, which may indicate acute respiratory distress syndrome, a rare inflammatory lung reaction.
• Rash, hives, facial swelling, wheezing, or dizziness, the signs of an allergic reaction.
• Swelling in the limbs or abdomen with dizziness and reduced urination, features of capillary leak syndrome, in which fluid escapes from small blood vessels.
• Blood in the urine, foamy urine, or facial puffiness, which can point to kidney inflammation.

A laboratory finding rather than a symptom, an unusually high white cell count, is monitored through routine blood tests. Long-term questions, particularly whether G-CSF influences later marrow disorders, are discussed in the myths section below, because the evidence deserves careful framing.

Pegfilgrastim vs filgrastim: what the difference means in practice

The two most widely used G-CSF forms share a receptor, a mechanism, and most of their side effects. The differences lie in chemistry and convenience, and understanding them helps patients follow the reasoning behind their own prescription.

Filgrastim is the unmodified protein. The body clears it quickly through the kidneys and through binding to neutrophils, so keeping the signal going requires an injection every day during the vulnerable period. This has an upside: the team can stop the moment counts recover, and can start or pause with precision. It suits situations where flexibility matters, such as stem cell mobilization, chronic neutropenia, or chemotherapy given on schedules that do not fit a once-per-cycle model.

Pegfilgrastim attaches a chain of polyethylene glycol to the same protein. The chain makes the molecule too large for the kidneys to filter efficiently, so clearance depends almost entirely on neutrophils carrying it away. When counts are low, the drug lingers; as counts rise, it is removed. One injection therefore behaves like a course of daily shots that tapers itself. MedlinePlus describes its use as once per chemotherapy cycle, given at least 24 hours after chemotherapy and not within the 14 days before the next dose.

The practical trade-offs come down to a few questions. How often is chemotherapy given? Weekly regimens rarely leave room for a long-acting dose. Can the person or a caregiver manage daily injections comfortably? How far away is the clinic? Is there a reason to prefer fine control over convenience?

For most standard three-week chemotherapy cycles, either approach is considered reasonable in guideline literature, and the choice often rests on logistics and the patient’s preference as much as on biology. It is entirely appropriate to ask why one was chosen.

Do growth factor injections for neutropenia change cancer outcomes?

Here is where an honest answer needs to be more careful than the marketing surrounding these medicines. What the evidence shows clearly is this: G-CSF shortens the duration of severe neutropenia after chemotherapy and lowers the rate of febrile neutropenia and related hospital admissions. That finding is consistent across large trials and systematic reviews and is the reason every major oncology guideline includes these medicines.

Whether that translates into people living longer is a different question, and the data are less uniform. The most plausible route to a survival benefit is indirect: if neutropenia is kept in check, chemotherapy can be delivered on schedule and at the intended intensity, and for some cancers, dose intensity matters. Pooled analyses have suggested a modest reduction in early deaths, mostly from infection, but the size of any long-term effect varies by cancer type, regimen, and patient population. It would be misleading to present G-CSF as a treatment that improves cancer control by itself.

Equally important is what G-CSF does not do. It does not treat an infection that has already taken hold; that requires antibiotics and, often, hospital care. It does not raise red cells or platelets, so anemia and bleeding risk are unaffected. It does not make chemotherapy less nauseating or less tiring, although some people feel better simply because counts recover sooner.

A reasonable way to hold this is as risk reduction rather than treatment enhancement. The injection lowers the chance of a specific, dangerous complication. For someone whose chemotherapy carries a high risk of that complication, the value is substantial. For someone at low risk, the same injection offers less, which is exactly why teams do not prescribe it to everyone.

What people often get wrong about G-CSF

“It boosts my immune system.” Only one narrow part of it. G-CSF raises neutrophils, the front-line bacterial defenders. It does not strengthen lymphocytes, antibodies, or the body’s response to viruses. Handwashing, food safety, and avoiding sick contacts remain as relevant during treatment as before.

“If my count is high after the shot, I am safe.” An early spike, particularly in the first day or two, largely reflects stored neutrophils being pushed out rather than genuine recovery, and the count may dip again. Teams interpret timing alongside numbers; a single high value should not change how carefully fever is watched.

“The bone pain means something is going wrong.” Usually the opposite. Ache in the hips, back, or sternum reflects an expanding marrow inside rigid bone, a sign the medicine is doing its job. Severe pain still warrants a call, because relief is available and because pain in the upper left abdomen specifically needs urgent assessment.

“It will make the chemotherapy work better.” Not directly. Its role is to lower the risk of a specific complication and help keep treatment on schedule, as the previous section explains.

“These shots cause leukemia.” This concern deserves careful wording. In people with severe congenital neutropenia, a group already at elevated risk of developing myelodysplasia or leukemia because of the underlying genetic condition, registries have observed these events during long-term G-CSF use, and it has been difficult to separate the medicine’s contribution from the disease’s own trajectory. In people receiving G-CSF briefly around chemotherapy, some studies have reported a small association with later marrow disorders, but chemotherapy itself carries that risk, and the evidence does not establish causation. The right question to ask a hematologist is what the risk looks like for one’s own situation.

“Skipping a dose won’t matter.” Timing is built into how these medicines work; any change should go through the prescriber.

Questions to ask your care team before the first injection

A good consultation about growth factor support usually answers most of these on its own. Bringing them written down helps ensure none slip past, and it signals to the team that the person wants to understand the plan rather than simply follow it.

• Why is my regimen considered high enough risk to warrant this, and what would the plan be without it?
• Which type has been chosen, short-acting or long-acting, and what shaped that choice for me?
• Exactly when should each injection be given relative to my chemotherapy, and what should I do if I miss the window?
• Will I or a family member be giving the injections at home, and can we have a supervised practice run first?
• How will you know it is working, and how often will my blood be checked?
• What can I take or do for bone pain, and at what point should pain prompt a call rather than home management?
• Which symptoms mean I should go to an emergency department immediately, and which number do I call after hours?
• Is there anything in my history, such as sickle cell disease, a spleen condition, kidney disease, or a previous reaction to a biologic medicine, that changes how carefully this needs to be monitored?
• If this is a biosimilar, how does that affect my treatment, if at all?
• How will this affect the scheduling of my next chemotherapy cycle?
• For long-term or inherited neutropenia: what monitoring for marrow health is planned over the years, and how often?

Two habits make these conversations more productive. Ask the team to write down the injection schedule in plain terms, ideally on a calendar that also marks chemotherapy days. And ask who to contact when the clinic is closed, because febrile neutropenia does not keep office hours.

Every one of these questions has a legitimate answer. If any of them is met with a shrug, that is worth gently pursuing.

When to call your doctor: red-flag signs during growth factor treatment

Most of what follows applies to anyone with neutropenia, whether or not they are receiving injections, because the injection lowers risk without removing it. The single most important rule, echoed by Mayo Clinic and Cleveland Clinic, is that fever during a period of low counts is an emergency, not a wait-and-see symptom.

Seek emergency care immediately, day or night, for:

• A temperature of 100.4°F (38°C) or higher, or chills and shaking even without a confirmed fever
• Sudden shortness of breath, rapid breathing, or chest pain
• Pain in the upper left abdomen or the tip of the left shoulder, which can indicate a problem with the spleen
• Hives, facial or throat swelling, wheezing, or feeling faint after an injection
• Confusion, drowsiness, or a rapid heartbeat with low blood pressure, which can accompany sepsis
• Swelling of the arms, legs, or abdomen with dizziness and passing little urine

Call the care team the same day for:

• Blood in the urine, foamy urine, or new puffiness around the eyes
• Bone or muscle pain that home measures do not control or that keeps you from sleeping
• Redness, warmth, or increasing pain at an injection site that spreads rather than fades
• New mouth ulcers, a sore throat, burning on urination, cough, or any localized sign of infection
• A missed or mistimed injection, so the schedule can be adjusted safely

Remember that neutropenia can mute the ordinary signs of infection. There may be no pus, little redness, and only a modest fever. Feeling suddenly and inexplicably unwell is itself a reason to pick up the phone.

Nothing here should override individual instructions from the treating team, who know the regimen, the counts, and the person. When in doubt, call; clinicians would far rather hear about a false alarm than miss a real one.

Frequently asked questions

What are the growth factors for neutropenia?

The main growth factors for neutropenia are granulocyte colony-stimulating factors (G-CSF), available as short-acting filgrastim and its biosimilars and as long-acting pegfilgrastim, plus the less commonly used granulocyte-macrophage colony-stimulating factor (GM-CSF, sargramostim). All are manufactured copies of natural proteins that signal the marrow to produce neutrophils. The choice among them rests with the treating team.

Is filgrastim a growth factor?

Yes. Filgrastim is a recombinant form of granulocyte colony-stimulating factor, a hematopoietic growth factor, meaning a protein that stimulates blood cell production. It binds receptors on neutrophil precursors in the bone marrow, prompting them to divide, mature, and enter the bloodstream faster. It does not affect red cells, platelets, or lymphocytes, and it has no direct action against infection or cancer.

What injection is given for neutropenia after chemo?

A neutropenia injection after chemo is usually a G-CSF product, either daily short-acting filgrastim (or a biosimilar) or a single long-acting pegfilgrastim dose given the day after treatment. MedlinePlus notes both are timed at least 24 hours away from chemotherapy. Which is used depends on the regimen’s schedule, the person’s risk, and practical factors, all decided by the prescribing clinician.

What are the potential side effects of taking a growth factor shot?

The most common G-CSF injection side effects are bone and muscle pain, headache, tiredness, nausea, and soreness at the injection site, according to MedlinePlus. Rare but serious effects include spleen enlargement or rupture, acute lung inflammation, allergic reactions, capillary leak syndrome, kidney inflammation, and sickle cell crisis in people with sickle cell disease. New upper-left abdominal pain or breathlessness needs urgent assessment.

How does filgrastim work to raise white blood cells?

Filgrastim binds to G-CSF receptors on neutrophil precursors in the bone marrow, increasing how often they divide, shortening their maturation time, and releasing mature neutrophils into the blood earlier. Counts can rise within a day, per MedlinePlus, though an early spike partly reflects stored cells being released. It works only when the marrow retains precursors capable of responding to the signal.

Pegfilgrastim vs filgrastim: which one is better?

Neither is universally better; they share a mechanism and most side effects. Filgrastim is cleared within about a day and given daily, allowing fine control. Pegfilgrastim carries a polyethylene glycol chain that slows clearance so one injection covers a chemotherapy cycle, per MedlinePlus. Guidelines regard both as reasonable for standard cycles, and the choice usually turns on schedule, logistics, and preference.

Why do G-CSF injections cause bone pain?

The ache comes from the bone marrow expanding inside rigid bone as it rapidly increases neutrophil production, along with inflammatory signals released during that surge. It is most often felt in the lower back, hips, and breastbone and usually peaks in the first days after injection. Care teams have several strategies to ease it, so persistent or severe pain should always be reported rather than tolerated.

Does everyone on chemotherapy need growth factor injections?

No. Guidelines recommend G-CSF when the combined risk of febrile neutropenia from the regimen and the individual’s characteristics is judged high enough to justify it. People on lower-risk regimens with healthy marrow are often managed with regular blood counts and prompt treatment of any fever instead. Being offered monitoring rather than injections is a legitimate, evidence-based plan, not a lesser one.

Can growth factor injections cause leukemia?

The evidence does not establish that they do in people receiving short courses around chemotherapy, although small associations have been reported and chemotherapy itself carries that risk. In severe congenital neutropenia, a condition already prone to marrow disorders, registries have observed leukemia during long-term use, and separating drug from disease has proved difficult. A hematologist can explain what the data mean for an individual situation.

What temperature counts as an emergency during neutropenia?

A temperature of 100.4°F (38°C) or higher during a period of low neutrophils is treated as a medical emergency by Mayo Clinic and Cleveland Clinic, as are chills and shaking even without a measured fever. Because neutropenia can hide the usual signs of infection, feeling suddenly and unexpectedly unwell is also a reason to contact the care team or seek emergency care immediately.

References

• MedlinePlus: Filgrastim Injection
• MedlinePlus: Pegfilgrastim Injection
• Cleveland Clinic: Neutropenia

This article is for general information only and is not a substitute for professional medical advice. Please consult a qualified doctor about your individual situation.